Agilent Technologies Inc. is a leader in life sciences, diagnostics and applied chemical markets. The company provides laboratories worldwide with instruments, services, consumables, applications and expertise, enabling customers to gain the insights they seek. Agilent’s expertise and trusted collaboration give them the highest confidence in our solutions.
Representatives: Steve Fischer, Christine Miller
At Biognosys, we believe that knowledge of the proteome holds the answers to understanding the phenotypic behaviour of complex biological systems. Biognosys is dedicated to developing superior proteomics solutions and offers these solutions to researchers as products and services. These solutions rely on mass spectrometry with parallel data-independent acquisition (DIA), which allow simultaneous quantification of thousands of proteins in a single experiment. Our next generation technology provides multiplexed protein quantification with high precision and depth.
Representatives: Claudia Escher, Oliver Rinner
Bruker provides innovative mass spectrometry systems for proteomics that overcome long-standing limitations in speed, sensitivity and robustness. We offer a complete range of proteomics solutions to enhance analytical depth and throughput and to minimize maintenance and downtime.
Representatives: Gary Kruppa, Pierre-Olivier Schmit
Cambridge Isotope Laboratories, Inc (CIL) is the world leader in the manufacture of stable isotopes (e.g., 13C, D, 15N) and their compounds for qualitative and quantitative, MS 'omics applications. Proteomic products include QC and quantitation kits, peptide and protein starting materials, SILAC and SILAM reagents/kits, chemical tagging reagents, and enzymatic labeling reagents.
Representatives: Joel Louette, Andrew Percy
EVOSEP aims to improve quality of life and patient care by radically innovating protein based clinical diagnostics. Making sample preparation and separation before MS analysis 10 times faster and 100 times more robust will enable truly large cohort studies for biomarker validation and provide the foundation for precision medicine.
Representatives: Michael Andersen, Nicolai Bache
Newomics Inc. is a commercial stage biotechnology company in the San Francisco bay area. It is dedicated to creating and commercializing innovative (New) and integrative (Omics) platforms and solutions for precision medicine. Its products include silicon-based multinozzle emitters (M3 emitters) and microfluidic LC-MS chips (MEA chips) that significantly increase the sensitivity and robustness of mass spectrometry.
Representative: Daojing Wang
Sengenics is a functional proteomics and research and diagnostics company, with a range of proprietary and patented technologies and products. The main focus of the company is leveraging on our core patented Immunome protein array technology for discovering antibody-based therapeutics and diagnostic signatures for immune system disorders. The Immunome protein array platform was originally developed as a collaboration between the University of Oxford and the University of Cambridge, by Professor Jonathan Blackburn.
Representatives: Johan Poole-Johnson, Jonathan Blackburn
SCIEX solutions for biomarker & omics research enable scientists to push the limits in discovery proteomics, targeted peptide quantitation, lipidomics, metabolomics, protein characterization, and tissue imaging.
Representative: Arianna Jones, Tom Knapman
Thermo Scientific is the leading source of innovative, comprehensive workflow solutions to address the most challenging aspects of proteomics research.
Representatives: Aran Paulus, Julian Saba
PeakInvestigator® post-MS signal-processing software differentiates peak signals from noise with statistical confidence intervals, and deconvolves overlapped peaks with 5-6x higher resolution, revealing critical hidden information. PeakInvestigator operates on raw profile MS data for all sample types, from ion trap, TOF, Orbitrap and FTICR mass analyzers. PeptideDetective® software (alpha), outperforms current market leaders in de novo peptide identifications.
Representatives: Jeff Peterson, Mark Duncan
From biomarker discovery and translational research through to clinical diagnostic solutions, at Waters, we strive to improve human health by partnering with the biomedical community to help make breakthrough scientific discoveries and translate them into healthcare solutions.
Representatives: David Heywood, Roy Martin